Shanghai Haohai Biological Technology Co., Ltd. Class H (6826) AI Stock Analysis

• Market Cap: HK$12.15B
• Dividend Yield: 3.99%
• Average Volume (3M): 522.14K
• Price to Earnings (P/E): 14.5
• Beta (1Y): 0.99
• Revenue Growth: -5.62%
• EPS Growth: -9.71%
• Country: HK
• Employees: 2,156
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.99
• Shares Outstanding: 38,529,240
• 10 Day Avg. Volume: 397,015
• 30 Day Avg. Volume: 522,143
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: HK$33.00
• Price Target Upside: 20.53% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 0

• Rating: 70 Outperform
• Price Target: HK$29.00 ▲(5.92% Upside)

The overall stock score of 70 reflects strong financial performance and reasonable valuation, offset by bearish technical indicators. The company's robust revenue growth and profitability are significant strengths, but missing data for 2024 and bearish market momentum present challenges. The attractive dividend yield adds a positive aspect for income-focused investors.

Shanghai Haohai Biological Technology Co., Ltd. Class H Business Overview & Revenue Model

Company Description

Shanghai Haohai Biological Technology Co., Ltd. engages in the research, development, manufacture, and sale of biomedical materials in Mainland China, the United States, the United Kingdom, and internationally. It offers ophthalmology products comprising intraocular lens, ophthalmic viscoelastic devices, orthokeratology and phakic refractive lenses, eye drops, injectors, scalpels, etc.; orthopedics products, such as sodium hyaluronate injection and medical chitosan; wound repair products, including recombinant human epidermal growth factor for the treatment of burn wound, residual wound, donor site posttraumatic wound, and fresh or old wound of chronic ulcer; anti-adhesion materials comprising medical sodium hyaluronate gel and medical chitosan; and hemostatic materials, such as collagen sponge and porcine fibrin sealants. The company also provides medical aesthetics products comprising Matrifill, a first-generation HA dermal filler, which is a mono-phase sodium hyaluronate gel for injection; Janlane, a second-generation HA dermal filler for dynamic filling function; Hyalumatrix, a third-generation HA dermal filler that offers precise embellishment function; and radio frequency devices and laser equipment. In addition, it is involved in research and development of biological engineering and pharmaceutical products, as well as in the provision of related technology transfer, and consultation services; and investment and trading business. The company was formerly known as Haohai Limited and changed its name to Shanghai Haohai Biological Technology Co., Ltd. in 2010. Shanghai Haohai Biological Technology Co., Ltd. was founded in 2007 and is headquartered in Shanghai, China.

How the Company Makes Money

Shanghai Haohai Biological Technology Co., Ltd. generates revenue primarily through the sale of its diverse range of medical and pharmaceutical products. The company's key revenue streams include ophthalmic products used in eye surgeries, medical aesthetics products for cosmetic procedures, and orthopedic products for bone and joint health. Additionally, it offers anti-adhesion and hemostatic solutions used in surgical procedures. The company also benefits from strategic partnerships and collaborations with healthcare providers, research institutions, and distributors, which enhance its market presence and distribution capabilities. These partnerships, along with a strong emphasis on research and development, contribute significantly to its earnings by driving product innovation and expanding its market reach.

Shanghai Haohai Biological Technology Co., Ltd. Class H Financial Statement Overview

Summary

Shanghai Haohai Biological Technology Co., Ltd. demonstrates strong revenue growth and profitability, supported by a robust balance sheet with low leverage. However, missing data in 2024 for key metrics could pose future analytical challenges. The company should focus on maintaining operational efficiency and improving cash flow visibility.

Income Statement

The company's revenue has shown consistent growth, with a notable increase from 2022 to 2023. The gross profit margin remains strong, indicating efficient cost management. Net income has also increased, demonstrating profitability. However, there is a slight decline in EBITDA margin, which could indicate rising operational costs.

Balance Sheet

The company has a strong equity position, with liabilities being significantly lower than stockholders' equity, leading to a healthy debt-to-equity ratio. However, the absence of total assets in 2024 data makes it challenging to calculate key ratios like equity ratio and return on equity (ROE) for the latest year.

Cash Flow

Operating cash flow showed substantial growth in 2023 but is missing for 2024, which raises concerns about cash management. The free cash flow turned positive in 2023, showing improved cash efficiency. However, the lack of data for 2024 limits further analysis.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.67B	2.68B	2.63B	2.10B	1.75B	1.32B
Gross Profit	1.47B	1.87B	1.85B	1.45B	1.26B	990.42M
EBITDA	643.57M	665.04M	713.41M	447.55M	550.45M	394.80M
Net Income	412.92M	420.45M	416.12M	180.47M	352.23M	230.07M
Balance Sheet
Total Assets	7.13B	7.12B	7.11B	6.89B	6.95B	6.30B
Cash, Cash Equivalents and Short-Term Investments	2.66B	2.76B	2.75B	2.54B	2.91B	3.11B
Total Debt	452.51M	448.43M	407.95M	118.26M	105.51M	108.08M
Total Liabilities	1.18B	1.20B	1.09B	990.02M	890.07M	564.46M
Stockholders Equity	5.67B	5.58B	5.65B	5.51B	5.71B	5.49B
Cash Flow
Free Cash Flow	254.80M	283.08M	367.22M	-85.85M	70.19M	66.21M
Operating Cash Flow	440.55M	648.57M	634.45M	231.30M	342.29M	262.07M
Investing Cash Flow	-183.48M	282.28M	-376.65M	-681.82M	-148.09M	316.92M
Financing Cash Flow	-511.56M	-390.35M	-257.73M	-288.35M	-231.25M	-190.06M

Shanghai Haohai Biological Technology Co., Ltd. Class H Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 27.38
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6826, the sentiment is Negative. The current price of 27.38 is below the 20-day moving average (MA) of 27.52, below the 50-day MA of 28.18, and above the 200-day MA of 25.80, indicating a neutral trend. The MACD of -0.16 indicates Positive momentum. The RSI at 42.52 is Neutral, neither overbought nor oversold. The STOCH value of 17.78 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:6826.

Shanghai Haohai Biological Technology Co., Ltd. Class H Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
6826	70 Outperform	HK$12.15B	14.48	6.98%	3.99%	-5.62%	-9.71%
2315	66 Neutral	10.87B	76.05	4.02%	―	48.38%	0.00%
2157	57 Neutral	13.49B	-64.48	-58.53%	―	240.05%	-140.09%
2162	55 Neutral	20.69B	-72.04	-20.82%	―	964.40%	65.90%
2171	53 Neutral	11.68B	-20.40	0.00%	―	1219.19%	25.15%
1672	46 Neutral	11.49B	-40.39	-15.31%	―	-76.58%	-4.90%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Shanghai Haohai Biological Technology Co., Ltd. Class H Corporate Events

Shanghai Haohai Biological Announces Interim Dividend for 2025

Shanghai Haohai Biological Technology Co., Ltd. has announced an interim cash dividend of RMB 0.4 per share for the six-month period ending June 30, 2025. The dividend will be paid in Hong Kong dollars at an exchange rate of RMB 1 to HKD 1.096155, with a payment date set for October 17, 2025. The announcement reflects the company’s financial health and commitment to returning value to its shareholders. The dividend distribution also involves withholding tax implications for both resident and non-resident shareholders, with varying rates based on residency and applicable tax treaties.

The most recent analyst rating on (HK:6826) stock is a Buy with a HK$33.00 price target. To see the full list of analyst forecasts on Shanghai Haohai Biological Technology Co., Ltd. Class H stock, see the HK:6826 Stock Forecast page.

Shanghai Haohai Reports Decline in Revenue and Profit for H1 2025

Shanghai Haohai Biological Technology Co., Ltd. reported a decrease in revenue and profit for the six-month period ending June 30, 2025, compared to the same period in 2024. Revenue fell by approximately 7.48% to RMB1,292.64 million, while profit attributable to ordinary equity holders decreased by 10.29% to RMB211.07 million. Despite these declines, the company maintained its interim dividend at RMB0.40 per share. The decrease in R&D expenses by 21.53% and a slight improvement in other income and gains were notable financial movements during the period.

The most recent analyst rating on (HK:6826) stock is a Buy with a HK$33.00 price target. To see the full list of analyst forecasts on Shanghai Haohai Biological Technology Co., Ltd. Class H stock, see the HK:6826 Stock Forecast page.

Shanghai Haohai Announces 2025 Interim Dividend Distribution

Shanghai Haohai Biological Technology Co., Ltd. has announced the distribution and payment of an interim dividend for 2025, amounting to RMB0.40 per share, totaling RMB91,493,200.00. The dividend will be distributed to H Shareholders in Hong Kong Dollars, with payments scheduled for October 17, 2025. The company has also outlined tax arrangements for non-resident enterprise shareholders and individual holders of H shares, ensuring compliance with the Enterprise Income Tax Law of the People’s Republic of China.

The most recent analyst rating on (HK:6826) stock is a Buy with a HK$33.00 price target. To see the full list of analyst forecasts on Shanghai Haohai Biological Technology Co., Ltd. Class H stock, see the HK:6826 Stock Forecast page.

Shanghai Haohai Biological Technology Schedules Board Meeting for Interim Results

Shanghai Haohai Biological Technology Co., Ltd. has announced that its board of directors will meet on August 22, 2025, to review and approve the interim results for the first half of the year ending June 30, 2025. The meeting will also consider the possibility of declaring an interim dividend, which could impact shareholder returns and reflect the company’s financial health.

Shanghai Haohai Adjusts A Shares Repurchase Price Cap

Shanghai Haohai Biological Technology Co., Ltd. announced an adjustment to the share price cap for its A shares repurchase plan. The company has reduced the maximum repurchase price to RMB88.72 per share following the approval of its 2024 profit distribution plan and the completion of the final dividend distribution. This adjustment is part of the company’s ongoing strategy to manage its share capital effectively, adhering to relevant regulations and market conditions.

Shanghai Haohai Biological Technology Announces Board Composition

Shanghai Haohai Biological Technology Co., Ltd. has announced the composition of its board of directors, highlighting the roles and functions of each member. The board consists of executive, non-executive, and independent non-executive directors, with various members serving on four key committees: Audit, Remuneration and Review, Nomination, and Strategy and Sustainable Development. This announcement underscores the company’s commitment to structured governance and strategic oversight, potentially impacting its operational efficiency and stakeholder confidence.

Shanghai Haohai Enhances Governance with New Audit Committee

Shanghai Haohai Biological Technology Co., Ltd. has established an audit committee to enhance its corporate governance and financial oversight. The committee is responsible for reviewing financial information, supervising audits, and ensuring effective management oversight, which is expected to strengthen the company’s decision-making and governance structure.

Shanghai Haohai Biological Technology Enhances Governance with New Remuneration Committee

Shanghai Haohai Biological Technology Co., Ltd. has established a remuneration and appraisal committee under its Board of Directors to enhance its remuneration management system. This committee is responsible for setting performance evaluation indicators and remuneration systems for directors and senior management, ensuring a formal and transparent process for developing remuneration policies, and making recommendations on remuneration packages. The move aims to align the company’s governance with regulatory requirements and improve oversight of executive compensation, potentially impacting its market positioning and stakeholder confidence.

Shanghai Haohai Enhances Governance with New Nomination Committee

Shanghai Haohai Biological Technology Co., Ltd. has established a Nomination Committee under its Board of Directors to enhance corporate governance. This committee is responsible for setting criteria and procedures for selecting directors and senior management, ensuring the board’s composition aligns with the company’s strategic goals, and maintaining board diversity. This move aims to optimize board operations and improve decision-making processes, which could strengthen the company’s industry positioning and stakeholder confidence.

Shanghai Haohai Biological Technology Approves Key Resolutions at Annual Meetings

Shanghai Haohai Biological Technology Co., Ltd. successfully held its Annual General Meeting and class meetings for A and H shareholders, where all proposed resolutions were approved. Significant decisions included the 2024 profit distribution, election of a new board session, and the abolishment of the supervisory committee, which are expected to impact the company’s governance and operational strategies.